Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 310

1.

50 Patients with Malignant Mesothelioma of Both the Pleura and Peritoneum: A Single-Institution Experience.

Letica-Kriegel AS, Leinwand JC, Sonett JR, Gorenstein LA, Taub RN, Chabot JA, Kluger MD.

Ann Surg Oncol. 2019 May 7. doi: 10.1245/s10434-019-07409-5. [Epub ahead of print]

PMID:
31065962
2.

Immunohistochemistry in Peritoneal Mesothelioma: A Single-Center Experience of 244 Cases.

Tandon RT, Jimenez-Cortez Y, Taub R, Borczuk AC.

Arch Pathol Lab Med. 2018 Feb;142(2):236-242. doi: 10.5858/arpa.2017-0092-OA. Epub 2017 Oct 19.

PMID:
29048219
3.

Recurrence of Optimally Treated Malignant Peritoneal Mesothelioma with Cytoreduction and Heated Intraperitoneal Chemotherapy.

Heller DR, Chiuzan C, Taub RN, Leinwand JC, Greene AM, Bates GE, Chabot JA, Kluger MD.

Ann Surg Oncol. 2017 Dec;24(13):3818-3824. doi: 10.1245/s10434-017-6106-x. Epub 2017 Oct 12.

PMID:
29027138
4.

Cervical mucus and contraception: what we know and what we don't.

Han L, Taub R, Jensen JT.

Contraception. 2017 Nov;96(5):310-321. doi: 10.1016/j.contraception.2017.07.168. Epub 2017 Aug 8. Review.

PMID:
28801053
5.

Advances in contraception: new options for postpartum women.

Taub RL, Jensen JT.

Expert Opin Pharmacother. 2017 May;18(7):677-688. doi: 10.1080/14656566.2017.1316370. Epub 2017 Apr 17. Review.

PMID:
28375776
6.

Long-term flecainide therapy in type 3 long QT syndrome.

Chorin E, Taub R, Medina A, Flint N, Viskin S, Benhorin J.

Europace. 2018 Feb 1;20(2):370-376. doi: 10.1093/europace/euw439.

PMID:
28339995
7.

Mindfulness-based group therapy for systemic lupus erythematosus: A first exploration of a promising mind-body intervention.

Horesh D, Glick I, Taub R, Agmon-Levin N, Shoenfeld Y.

Complement Ther Clin Pract. 2017 Feb;26:73-75. doi: 10.1016/j.ctcp.2016.11.011. Epub 2016 Nov 29.

PMID:
28107854
8.

Intimacy, Body Image, and Cancer.

Bates G, Taub RN, West HJ.

JAMA Oncol. 2016 Dec 1;2(12):1667. doi: 10.1001/jamaoncol.2016.1196. No abstract available.

PMID:
27711916
9.

PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma.

Ryan CW, Merimsky O, Agulnik M, Blay JY, Schuetze SM, Van Tine BA, Jones RL, Elias AD, Choy E, Alcindor T, Keedy VL, Reed DR, Taub RN, Italiano A, Garcia Del Muro X, Judson IR, Buck JY, Lebel F, Lewis JJ, Maki RG, Schöffski P.

J Clin Oncol. 2016 Nov 10;34(32):3898-3905. doi: 10.1200/JCO.2016.67.6684. Epub 2016 Sep 30.

PMID:
27621408
10.

Approach to offering remote support to mesothelioma patients: the mesothelioma survivor project.

Bates GE, Hashmi AK, Bressler T, Zajac J, Hesdorffer M, Taub RN.

Transl Lung Cancer Res. 2016 Jun;5(3):216-8. doi: 10.21037/tlcr.2016.05.05.

11.

Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration.

Borczuk AC, Pei J, Taub RN, Levy B, Nahum O, Chen J, Chen K, Testa JR.

Cancer Biol Ther. 2016;17(3):328-35. doi: 10.1080/15384047.2016.1145850. Epub 2016 Feb 6.

12.

Fertility and Cancer Treatment.

Bates GE, Taub RN, West H.

JAMA Oncol. 2016 Feb;2(2):284. doi: 10.1001/jamaoncol.2015.4143. No abstract available.

PMID:
26822339
13.

Prognostic significance of morphological growth patterns and mitotic index of epithelioid malignant peritoneal mesothelioma.

Krasinskas AM, Borczuk AC, Hartman DJ, Chabot JA, Taub RN, Mogal A, Pingpank J, Bartlett D, Dacic S.

Histopathology. 2016 Apr;68(5):729-37. doi: 10.1111/his.12807. Epub 2015 Oct 16.

PMID:
26272336
14.

A phase 2 randomized, double-blind, placebo-controlled study of the effect of VIA-2291, a 5-lipoxygenase inhibitor, on vascular inflammation in patients after an acute coronary syndrome.

Gaztanaga J, Farkouh M, Rudd JH, Brotz TM, Rosenbaum D, Mani V, Kerwin TC, Taub R, Tardif JC, Tawakol A, Fayad ZA.

Atherosclerosis. 2015 May;240(1):53-60. doi: 10.1016/j.atherosclerosis.2015.02.027. Epub 2015 Feb 24.

PMID:
25752438
15.

Protein tyrosine phosphatase of liver regeneration-1 is required for normal timing of cell cycle progression during liver regeneration.

Jiao Y, Ye DZ, Li Z, Teta-Bissett M, Peng Y, Taub R, Greenbaum LE, Kaestner KH.

Am J Physiol Gastrointest Liver Physiol. 2015 Jan 15;308(2):G85-91. doi: 10.1152/ajpgi.00084.2014. Epub 2014 Nov 6.

16.

Discovery of camphor-derived pyrazolones as 11β-hydroxysteroid dehydrogenase type 1 inhibitors.

Gillespie P, Pietranico-Cole S, Myers M, Bilotta JA, Conde-Knape K, Fotouhi N, Goodnow RA Jr, Guertin KR, Hamilton MM, Haynes NE, Liu B, Qi L, Ren Y, Scott NR, So SS, Spence C, Taub R, Thakkar K, Tilley JW, Zwingelstein C.

Bioorg Med Chem Lett. 2014 Jun 15;24(12):2707-11. doi: 10.1016/j.bmcl.2014.04.049. Epub 2014 Apr 21.

PMID:
24815509
17.

Clinical utility of 18F-FDG positron emission tomography in malignant peritoneal mesothelioma.

Domènech-Vilardell A, Rasiej MJ, Taub RN, Ichise M.

Q J Nucl Med Mol Imaging. 2016 Mar;60(1):54-61. Epub 2014 Apr 14.

PMID:
24727854
18.

Discovery of 2-[3,5-dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β agonist in clinical trials for the treatment of dyslipidemia.

Kelly MJ, Pietranico-Cole S, Larigan JD, Haynes NE, Reynolds CH, Scott N, Vermeulen J, Dvorozniak M, Conde-Knape K, Huang KS, So SS, Thakkar K, Qian Y, Banner B, Mennona F, Danzi S, Klein I, Taub R, Tilley J.

J Med Chem. 2014 May 22;57(10):3912-23. doi: 10.1021/jm4019299. Epub 2014 Apr 8.

PMID:
24712661
19.

Lipid lowering in healthy volunteers treated with multiple doses of MGL-3196, a liver-targeted thyroid hormone receptor-β agonist.

Taub R, Chiang E, Chabot-Blanchet M, Kelly MJ, Reeves RA, Guertin MC, Tardif JC.

Atherosclerosis. 2013 Oct;230(2):373-80. doi: 10.1016/j.atherosclerosis.2013.07.056. Epub 2013 Aug 21.

PMID:
24075770
20.

Quantitative X-ray computed tomography peritoneography in malignant peritoneal mesothelioma patients receiving intraperitoneal chemotherapy.

Leinwand JC, Zhao B, Guo X, Krishnamoorthy S, Qi J, Graziano JH, Slavkovic VN, Bates GE, Lewin SN, Allendorf JD, Chabot JA, Schwartz LH, Taub RN.

Ann Surg Oncol. 2013 Dec;20 Suppl 3:S553-9. doi: 10.1245/s10434-013-2976-8. Epub 2013 May 24.

21.

Body surface area predicts plasma oxaliplatin and pharmacokinetic advantage in hyperthermic intraoperative intraperitoneal chemotherapy.

Leinwand JC, Bates GE, Allendorf JD, Chabot JA, Lewin SN, Taub RN.

Ann Surg Oncol. 2013 Apr;20(4):1101-4. doi: 10.1245/s10434-012-2790-8. Epub 2013 Mar 2.

22.

A multicenter phase II study of cisplatin, pemetrexed, and bevacizumab in patients with advanced malignant mesothelioma.

Dowell JE, Dunphy FR, Taub RN, Gerber DE, Ngov L, Yan J, Xie Y, Kindler HL.

Lung Cancer. 2012 Sep;77(3):567-71. doi: 10.1016/j.lungcan.2012.05.111. Epub 2012 Jul 4.

PMID:
22770372
23.

Utility of glucose transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions.

Lagana SM, Taub RN, Borczuk AC.

Arch Pathol Lab Med. 2012 Jul;136(7):804-9. doi: 10.5858/arpa.2011-0219-OA.

PMID:
22742553
24.

PPARγ agonists enhance ET-743-induced adipogenic differentiation in a transgenic mouse model of myxoid round cell liposarcoma.

Charytonowicz E, Terry M, Coakley K, Telis L, Remotti F, Cordon-Cardo C, Taub RN, Matushansky I.

J Clin Invest. 2012 Mar;122(3):886-98. doi: 10.1172/JCI60015. Epub 2012 Feb 1.

25.

Discovery and optimization of 2-phenyloxazole derivatives as diacylglycerol acyltransferase-1 inhibitors.

Yun W, Ahmad M, Chen Y, Gillespie P, Conde-Knape K, Kazmer S, Li S, Qian Y, Taub R, Wertheimer SJ, Whittard T, Bolin D.

Bioorg Med Chem Lett. 2011 Dec 1;21(23):7205-9. doi: 10.1016/j.bmcl.2011.09.039. Epub 2011 Sep 22.

PMID:
22001092
26.
27.

Anti-inflammatory therapeutics for the treatment of atherosclerosis.

Charo IF, Taub R.

Nat Rev Drug Discov. 2011 May;10(5):365-76. doi: 10.1038/nrd3444. Review.

28.

Adjuvant chemotherapy in 2011 for patients with soft-tissue sarcoma.

Matushansky I, Taub RN.

Nat Rev Clin Oncol. 2011 Mar 22;8(7):434-8. doi: 10.1038/nrclinonc.2011.36. Review.

PMID:
21423256
29.

Discovery of orally active carboxylic acid derivatives of 2-phenyl-5-trifluoromethyloxazole-4-carboxamide as potent diacylglycerol acyltransferase-1 inhibitors for the potential treatment of obesity and diabetes.

Qian Y, Wertheimer SJ, Ahmad M, Cheung AW, Firooznia F, Hamilton MM, Hayden S, Li S, Marcopulos N, McDermott L, Tan J, Yun W, Guo L, Pamidimukkala A, Chen Y, Huang KS, Ramsey GB, Whittard T, Conde-Knape K, Taub R, Rondinone CM, Tilley J, Bolin D.

J Med Chem. 2011 Apr 14;54(7):2433-46. doi: 10.1021/jm101580m. Epub 2011 Mar 17.

PMID:
21413799
30.

Two-stage operative cytoreduction and intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma: Operative morbidity and mortality in phase I and II trials.

Kluger MD, Taub RN, Hesdorffer M, Jin Z, Chabot JA.

Eur J Surg Oncol. 2010 Oct;36(10):997-1003. doi: 10.1016/j.ejso.2010.07.001. Epub 2010 Aug 2.

PMID:
20674253
31.

Iyengar yoga for young adults with rheumatoid arthritis: results from a mixed-methods pilot study.

Evans S, Moieni M, Taub R, Subramanian SK, Tsao JC, Sternlieb B, Zeltzer LK.

J Pain Symptom Manage. 2010 May;39(5):904-13. doi: 10.1016/j.jpainsymman.2009.09.018.

PMID:
20471550
32.

Treatment with 5-lipoxygenase inhibitor VIA-2291 (Atreleuton) in patients with recent acute coronary syndrome.

Tardif JC, L'allier PL, Ibrahim R, Grégoire JC, Nozza A, Cossette M, Kouz S, Lavoie MA, Paquin J, Brotz TM, Taub R, Pressacco J.

Circ Cardiovasc Imaging. 2010 May;3(3):298-307. doi: 10.1161/CIRCIMAGING.110.937169. Epub 2010 Feb 27.

PMID:
20190281
33.

Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology.

Janjan N, Lutz ST, Bedwinek JM, Hartsell WF, Ng A, Pieters RS Jr, Ratanatharathorn V, Silberstein EB, Taub RJ, Yasko AW, Rettenmaier A; American College of Radiology.

J Palliat Med. 2009 May;12(5):417-26. doi: 10.1089/jpm.2009.9633.

PMID:
19416037
34.

Extremes of clinical and enzymatic phenotypes in children with hyperinsulinism caused by glucokinase activating mutations.

Sayed S, Langdon DR, Odili S, Chen P, Buettger C, Schiffman AB, Suchi M, Taub R, Grimsby J, Matschinsky FM, Stanley CA.

Diabetes. 2009 Jun;58(6):1419-27. doi: 10.2337/db08-1792. Epub 2009 Mar 31.

35.

Phase II Study of Temozolomide and Thalidomide in Patients with Unresectable or Metastatic Leiomyosarcoma.

Boyar MS, Hesdorffer M, Keohan ML, Jin Z, Taub RN.

Sarcoma. 2008;2008:412503. doi: 10.1155/2008/412503. Epub 2008 Nov 16.

36.

Peritoneal mesothelioma.

Hesdorffer ME, Chabot J, DeRosa C, Taub R.

Curr Treat Options Oncol. 2008 Jun;9(2-3):180-90. doi: 10.1007/s11864-008-0072-2. Epub 2008 Oct 8. Review.

PMID:
18841478
37.

Epithelioid Angiosarcoma of the Small Intestine After Occupational Exposure to Radiation and Polyvinyl Chloride: A case Report and Review of Literature.

Khalil MF, Thomas A, Aassad A, Rubin M, Taub RN.

Sarcoma. 2005;9(3-4):161-4. doi: 10.1080/13577140500389069.

38.

Combined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma.

Hesdorffer ME, Chabot JA, Keohan ML, Fountain K, Talbot S, Gabay M, Valentin C, Lee SM, Taub RN.

Am J Clin Oncol. 2008 Feb;31(1):49-54. doi: 10.1097/COC.0b013e3180684181.

PMID:
18376228
39.

Sugar binding to recombinant wild-type and mutant glucokinase monitored by kinetic measurement and tryptophan fluorescence.

Zelent B, Odili S, Buettger C, Shiota C, Grimsby J, Taub R, Magnuson MA, Vanderkooi JM, Matschinsky FM.

Biochem J. 2008 Jul 15;413(2):269-80. doi: 10.1042/BJ20071718.

PMID:
18370929
40.

Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma.

Jänne PA, Simon GR, Langer CJ, Taub RN, Dowlati A, Fidias P, Monberg M, Obasaju C, Kindler H.

J Clin Oncol. 2008 Mar 20;26(9):1465-71. doi: 10.1200/JCO.2007.14.7611.

PMID:
18349397
41.

Potent, selective MCH-1 receptor antagonists.

Erickson SD, Banner B, Berthel S, Conde-Knape K, Falcioni F, Hakimi I, Hennessy B, Kester RF, Kim K, Ma C, McComas W, Mennona F, Mischke S, Orzechowski L, Qian Y, Salari H, Tengi J, Thakkar K, Taub R, Tilley JW, Wang H.

Bioorg Med Chem Lett. 2008 Feb 15;18(4):1402-6. doi: 10.1016/j.bmcl.2008.01.010. Epub 2008 Jan 8.

PMID:
18243691
42.

Considerable differences in vaccine immunogenicities and efficacies related to the diluent used for aluminum hydroxide adjuvant.

Lin L, Ibrahim AS, Avanesian V, Edwards JE Jr, Fu Y, Baquir B, Taub R, Spellberg B.

Clin Vaccine Immunol. 2008 Mar;15(3):582-4. doi: 10.1128/CVI.00427-07. Epub 2008 Jan 9.

43.

Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).

Kalmadi SR, Rankin C, Kraut MJ, Jacobs AD, Petrylak DP, Adelstein DJ, Keohan ML, Taub RN, Borden EC.

Lung Cancer. 2008 May;60(2):259-63. Epub 2007 Nov 19.

44.

Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy.

Taylor C, Hershman D, Shah N, Suciu-Foca N, Petrylak DP, Taub R, Vahdat L, Cheng B, Pegram M, Knutson KL, Clynes R.

Clin Cancer Res. 2007 Sep 1;13(17):5133-43.

45.

New strategies for treating GIST when imatinib fails.

Boyar MS, Taub RN.

Cancer Invest. 2007 Aug;25(5):328-35.

PMID:
17661208
46.

6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats.

Wong H, Dockens RC, Pajor L, Yeola S, Grace JE Jr, Stark AD, Taub RA, Yocca FD, Zaczek RC, Li YW.

Drug Metab Dispos. 2007 Aug;35(8):1387-92. Epub 2007 May 9.

PMID:
17494642
47.

Molecular profiling of malignant peritoneal mesothelioma identifies the ubiquitin-proteasome pathway as a therapeutic target in poor prognosis tumors.

Borczuk AC, Cappellini GC, Kim HK, Hesdorffer M, Taub RN, Powell CA.

Oncogene. 2007 Jan 25;26(4):610-7. Epub 2006 Jul 24.

PMID:
16862182
48.

A glucose sensor role for glucokinase in anterior pituitary cells.

Zelent D, Golson ML, Koeberlein B, Quintens R, van Lommel L, Buettger C, Weik-Collins H, Taub R, Grimsby J, Schuit F, Kaestner KH, Matschinsky FM.

Diabetes. 2006 Jul;55(7):1923-9.

49.

From clinicogenetic studies of maturity-onset diabetes of the young to unraveling complex mechanisms of glucokinase regulation.

Sagen JV, Odili S, Bjørkhaug L, Zelent D, Buettger C, Kwagh J, Stanley C, Dahl-Jørgensen K, de Beaufort C, Bell GI, Han Y, Grimsby J, Taub R, Molven A, Søvik O, Njølstad PR, Matschinsky FM.

Diabetes. 2006 Jun;55(6):1713-22.

50.

Current treatment options and biology of peritoneal mesothelioma: meeting summary of the first NIH peritoneal mesothelioma conference.

Hassan R, Alexander R, Antman K, Boffetta P, Churg A, Coit D, Hausner P, Kennedy R, Kindler H, Metintas M, Mutti L, Onda M, Pass H, Premkumar A, Roggli V, Sterman D, Sugarbaker P, Taub R, Verschraegen C.

Ann Oncol. 2006 Nov;17(11):1615-9. Epub 2006 Apr 6.

PMID:
16600983

Supplemental Content

Support Center